Research programme: anticancer therapeutics - NexusPharmaAlternative Names: p53-MDM2 Inhibitors - NexusPharma
Latest Information Update: 11 Oct 2010
At a glance
- Originator NexusPharma
- Class Small molecules
- Mechanism of Action Proto-oncogene protein c mdm2 inhibitors; Tumour suppressor protein p53 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 11 Oct 2010 Preclinical development is ongoing in Germany
- 09 Sep 2005 Preclinical trials in Cancer in Germany (unspecified route)